Fast Market Research

New Market Research Report: Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential

Recently published research from GBI Research, "Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential", is now available at Fast Market Research

 

Boston, MA -- (SBWIRE) -- 03/19/2013 -- GBI Research has released its latest research, "Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential". The report provides insights into the up-and-coming trends of a portion of the acquired orphan blood disorder pharmaceutical market by examining Idiopathic Thrombocytopenic Purpura (ITP), Myelodysplastic Syndrome (MDS), Myelofibrosis (MF), Paroxysmal Nocturnal Hemoglobinuria (PNH) and Polycythemia Vera (PV) in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan.

View Full Report Details and Table of Contents

The report includes market forecasts to 2019, detailed pipeline analysis, in-depth profiling of major products and details of recent industry deals.

The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts.

The MF market will be the fastest growing of the five markets during the forecast period, at a Compound Annual Growth Rate (CAGR) of 34% and reaching a total market size of $1.1bn in 2019. MDS represents the largest market, expected to reach $2.2bn by 2019.

Report Scope

- Current and future treatment trends for three rare diseases
- Market forecasts for five rare diseases across seven major markets
- Analysis of the developmental pipelines for five rare diseases
- Information on recent industry deals

Reasons to Get this Report

- Understand how the inherited orphan blood diseases market has developed and is continuing to develop within the featured markets
- Predict which products are likely to be most successful in the future
- Gain an understanding of the possible market available for specific products

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation
- Inherited Orphan Blood Disorders Therapeutics Market to 2019 - Breakthrough Drugs Remain Elusive Against Backdrop of High Unmet Need
- Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules
- Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
- Blood Disorders Therapeutics Market to 2017 - Patent Expiries of Lovenox, Plavix, Procrit/Epogen, Aranesp and Neulasta Will Slow Down Growth
- Celiac Disease - Pipeline Assessment and Market Forecasts to 2019
- Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology
- Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted
- Isis Pharmaceuticals, Inc. (ISIS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Orphan Drugs: Strategic Approaches for the Industry